Zhenfei Bi

2.4k total citations
20 papers, 509 citations indexed

About

Zhenfei Bi is a scholar working on Molecular Biology, Immunology and Infectious Diseases. According to data from OpenAlex, Zhenfei Bi has authored 20 papers receiving a total of 509 indexed citations (citations by other indexed papers that have themselves been cited), including 8 papers in Molecular Biology, 8 papers in Immunology and 3 papers in Infectious Diseases. Recurrent topics in Zhenfei Bi's work include Immune cells in cancer (4 papers), interferon and immune responses (3 papers) and SARS-CoV-2 and COVID-19 Research (3 papers). Zhenfei Bi is often cited by papers focused on Immune cells in cancer (4 papers), interferon and immune responses (3 papers) and SARS-CoV-2 and COVID-19 Research (3 papers). Zhenfei Bi collaborates with scholars based in China. Zhenfei Bi's co-authors include Xiawei Wei, Yuquan Wei, Yanlin Song, H. J. Yang, Yu Liu, Weiqi Hong, Xuelei Ma, Zhe Zhang, Fei Mo and Lu Sun and has published in prestigious journals such as SHILAP Revista de lepidopterología, PLoS ONE and European Journal of Pharmacology.

In The Last Decade

Zhenfei Bi

18 papers receiving 503 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Zhenfei Bi China 12 225 111 78 56 50 20 509
Francesca Margheri Italy 15 229 1.0× 120 1.1× 30 0.4× 58 1.0× 95 1.9× 28 566
Wenyan Ren China 11 241 1.1× 95 0.9× 35 0.4× 47 0.8× 38 0.8× 16 536
Zhan Qi China 15 275 1.2× 133 1.2× 32 0.4× 49 0.9× 42 0.8× 51 611
Xueting Liu China 15 269 1.2× 219 2.0× 63 0.8× 83 1.5× 115 2.3× 31 611
Eric J. Askeland United States 9 309 1.4× 125 1.1× 39 0.5× 95 1.7× 42 0.8× 10 626
Malini Basu India 13 351 1.6× 123 1.1× 43 0.6× 164 2.9× 70 1.4× 36 651
Xiaobin Ma China 12 155 0.7× 55 0.5× 52 0.7× 60 1.1× 57 1.1× 31 378

Countries citing papers authored by Zhenfei Bi

Since Specialization
Citations

This map shows the geographic impact of Zhenfei Bi's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Zhenfei Bi with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Zhenfei Bi more than expected).

Fields of papers citing papers by Zhenfei Bi

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Zhenfei Bi. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Zhenfei Bi. The network helps show where Zhenfei Bi may publish in the future.

Co-authorship network of co-authors of Zhenfei Bi

This figure shows the co-authorship network connecting the top 25 collaborators of Zhenfei Bi. A scholar is included among the top collaborators of Zhenfei Bi based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Zhenfei Bi. Zhenfei Bi is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Han, Xuejiao, Yuan Cheng, Dandan Wan, et al.. (2025). Enhancing antitumor immunity through the combination of cholesterolized TLR7 agonist liposomes and radiotherapy: a role for IL‐1β and the inflammasome pathway. Cancer Communications. 45(7). 794–812. 2 indexed citations
2.
3.
Liu, Fengrui, Senlin Li, Chengcheng Huang, et al.. (2025). Self-assembled nanoplatform-mediated co-delivery of brusatol to sensitize sorafenib for hepatocellular carcinoma treatment. RSC Advances. 15(15). 11675–11687.
4.
Luo, Jingwen, Fei Mo, Zhe Zhang, et al.. (2024). Engineered mitochondria exert potent antitumor immunity as a cancer vaccine platform. Cellular and Molecular Immunology. 21(11). 1251–1265. 4 indexed citations
5.
Lu, Tianqi, Ziqi Zhang, Zhenfei Bi, et al.. (2023). TFAM deficiency in dendritic cells leads to mitochondrial dysfunction and enhanced antitumor immunity through cGAS-STING pathway. Journal for ImmunoTherapy of Cancer. 11(3). e005430–e005430. 35 indexed citations
6.
He, Xuemei, Tingmei Zhao, H. J. Yang, et al.. (2023). Inhibiting mtDNA‐STING‐NLRP3/IL‐1β axis‐mediated neutrophil infiltration protects neurons in Alzheimer's disease. Cell Proliferation. 57(1). e13529–e13529. 24 indexed citations
7.
Song, Yanlin, et al.. (2022). Targeting RAS–RAF–MEK–ERK signaling pathway in human cancer: Current status in clinical trials. Genes & Diseases. 10(1). 76–88. 119 indexed citations
8.
Que, Haiying, Weiqi Hong, Tianxia Lan, et al.. (2022). Tripterin liposome relieves severe acute respiratory syndrome as a potent COVID-19 treatment. Signal Transduction and Targeted Therapy. 7(1). 399–399. 22 indexed citations
9.
Song, Yanlin, Yuan Cheng, Tianxia Lan, et al.. (2022). ERK inhibitor: A candidate enhancing therapeutic effects of conventional chemo-radiotherapy in esophageal squamous cell carcinoma. Cancer Letters. 554. 216012–216012. 5 indexed citations
10.
Zhang, Qiangsheng, Yiqian Zhang, Zhenfei Bi, et al.. (2022). Design, synthesis and evaluation of antitumor activity of selective PRMT6 inhibitors. European Journal of Medicinal Chemistry. 247. 115032–115032. 10 indexed citations
11.
Zhang, Qiangsheng, et al.. (2022). Design, Synthesis and Evaluation of Antitumor Activity of Selective PRMT6 Inhibitors. SSRN Electronic Journal. 1 indexed citations
12.
Li, Qingfang, Yuan Cheng, Zhe Zhang, et al.. (2022). Inhibition of ROCK ameliorates pulmonary fibrosis by suppressing M2 macrophage polarisation through phosphorylation of STAT3. Clinical and Translational Medicine. 12(10). e1036–e1036. 55 indexed citations
13.
Bi, Zhenfei, Weiqi Hong, Haiying Que, et al.. (2021). Inactivated SARS-CoV-2 induces acute respiratory distress syndrome in human ACE2-transgenic mice. Signal Transduction and Targeted Therapy. 6(1). 439–439. 26 indexed citations
14.
Bi, Zhenfei, Weiqi Hong, H. J. Yang, Shuaiyao Lu, & Xiaozhong Peng. (2021). Animal models for SARS‐CoV‐2 infection and pathology. SHILAP Revista de lepidopterología. 2(4). 548–568. 24 indexed citations
15.
He, Xuemei, Weiqi Hong, H. J. Yang, et al.. (2021). Spontaneous apoptosis of cells in therapeutic stem cell preparation exert immunomodulatory effects through release of phosphatidylserine. Signal Transduction and Targeted Therapy. 6(1). 270–270. 37 indexed citations
16.
Bi, Zhenfei, Lu Li, H. J. Yang, et al.. (2021). Graphene promotes lung cancer metastasis through Wnt signaling activation induced by DAMPs. Nano Today. 39. 101175–101175. 6 indexed citations
17.
Yuan, Xia, Wen Nie, Zhiyao He, et al.. (2020). Carbon black nanoparticles induce cell necrosis through lysosomal membrane permeabilization and cause subsequent inflammatory response. Theranostics. 10(10). 4589–4605. 53 indexed citations
18.
Li, Lu, Zhenfei Bi, Yuzhu Hu, et al.. (2020). Silver nanoparticles and silver ions cause inflammatory response through induction of cell necrosis and the release of mitochondria in vivo and in vitro. Cell Biology and Toxicology. 37(2). 177–191. 43 indexed citations
19.
Liu, Zongying, Yuan Xue, Ruixue Bai, et al.. (2017). PAMs ameliorates the imiquimod-induced psoriasis-like skin disease in mice by inhibition of translocation of NF-κB and production of inflammatory cytokines. PLoS ONE. 12(5). e0176823–e0176823. 25 indexed citations
20.
Bi, Zhenfei, Wenrong Liu, Yiran Wu, et al.. (2016). A novel peptide, 9R-P201, strongly inhibits the viability, proliferation and migration of liver cancer HepG2 cells and induces apoptosis by down-regulation of FoxM1 expression. European Journal of Pharmacology. 796. 175–189. 18 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Francesca Margheri Breakdown of academic impact, for papers by Wenyan Ren Breakdown of academic impact, for papers by Zhan Qi Breakdown of academic impact, for papers by Xueting Liu Breakdown of academic impact, for papers by Eric J. Askeland Breakdown of academic impact, for papers by Malini Basu Breakdown of academic impact, for papers by Xiaobin Ma
Rankless by CCL
2026